|
|||||
|
|
Commentary: Sorafenib—The End of a Long Journey in Search of Systemic Therapy for Hepatocellular Carcinoma,or the Beginning? |
|
| Authors: | Ghassan K. Abou‐Alfa |
| Affiliation: | Memorial Sloan‐Kettering Cancer Center, New York, New York, USA |
| Abstract: | |
| Keywords: | |